{"filing":{"accession_number":"0001651308-26-000020","cik":"0001651308","ticker":"BEIGF","company_name":"BeOne Medicines Ltd.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"bgne-20260626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000020/bgne-20260626.htm"},"events":[{"id":14082,"run_id":12521,"accession_number":"0001651308-26-000020","anchor_item_number":"8.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"BeOne Medicines discloses settlement of a statutory tax audit in China resulting in an income tax payment of approximately RMB 446 million (including surcharges and interest) to be recognized in Q2 2026 financial statements. This is a material financial obligation arising from a concluded tax audit settlement, but does not fit the specific categories of debt_issuance, covenant_breach, or material_litigation. The event is clearly financial in nature and represents a significant charge to earnings, making financial_other the most appropriate classification.","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11413,"accession_number":"0001651308-26-000020","item_number":"8.01","item_title":"Other Events.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"BeOne Medicines discloses settlement of a statutory tax audit in China resulting in an income tax payment of approximately RMB 446 million (including surcharges and interest) to be recognized in Q2 2026 financial statements. This is a material financial obligation arising from a concluded tax audit settlement, but does not fit the specific categories of debt_issuance, covenant_breach, or material_litigation. The event is clearly financial in nature and represents a significant charge to earnings, making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:08:03.739625+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11413,"accession_number":"0001651308-26-000020","item_number":"8.01","item_title":"Other Events.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"BeOne Medicines discloses settlement of a statutory tax audit in China resulting in an income tax payment of approximately RMB 446 million (including surcharges and interest) to be recognized in Q2 2026 financial statements. This is a material financial obligation arising from a concluded tax audit settlement, but does not fit the specific categories of debt_issuance, covenant_breach, or material_litigation. The event is clearly financial in nature and represents a significant charge to earnings, making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:08:03.739625+00:00","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-06-26"}]}